Clinical Trial Update: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer [Phase 3]

View source ↗

Summary

Phase III trial evaluating ESG401 for locally advanced or metastatic HR+/HER2- breast cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• ESG401

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Metastatic Breast Cancer | Phase 3 | Status: RECRUITING